3 August 2011 -- For further information about Vernalis, please visit www.vernalis.com Vernalis plc announces that Nigel Sheail has today been appointed to the Board as a Non-
Executive Director.
Nigel is the Head of Corporate Mergers & Acquisitions and Global Head of Pharma
Licensing at Hoffmann-La Roche. After qualifying as a Chartered Accountant with Ernst and
Young, and a few years with Glaxo, Nigel has spent much of his career with Hoffman-La
Roche where he has held a variety of positions in the US, China and Switzerland in corporate
finance, licensing and strategic alliances.
Peter Fellner, Chairman of Vernalis plc, commented:
"I am delighted to welcome Nigel to the Vernalis Board. His depth of experience in the
global pharmaceutical industry will be very valuable for the Board, and we look forward to
his contribution, as we seek to build future value for Vernalis shareholders.”
Enquiries:
Vernalis Contacts
Ian Garland, Chief Executive Officer
+44 (0) 118 989 9360
David Mackney, Chief Financial Officer
Brunswick Group
Jon Coles
+44 (0) 20 7404 5959
Kristin Shine
Taylor Rafferty
Rob Newman
+44 (0) 20 7614 2900
Faisal Kanth
About Vernalis
Vernalis is a revenue generating development stage pharmaceutical company with significant
expertise in taking promising product candidates along a commercially-focused path to
market. The Group has one marketed product, frovatriptan for the acute treatment of
migraine, and eight candidates in development, seven of which are designated priority
programmes. Four of these priority development programmes are currently unpartnered and
three are partnered. Pipeline programmes are derived from both our own research activities
where we have significant expertise in fragment and structure based drug discovery, as well
as from collaborations. Our technologies, capabilities and products are endorsed by
collaborations with Endo, GSK, Lundbeck, Menarini, Novartis and Servier.